RCS - Physiomics PLC - Collaboration with The University of Sheffield

PhysiomicsAnnouncement

31/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230531:nRSe0681Ba&default-theme=true

RNS Number : 0681B  Physiomics PLC  31 May 2023

31 May 2023

 

Physiomics plc

("Physiomics" or the "Company")

 

Collaboration with The University of Sheffield

 

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting
oncology drug development and personalised medicine solutions, is pleased to
announce that it is supporting The University of Sheffield (the "University")
with research into an insect (Drosophila melanogaster) model of cancer
treatment that could be used to screen potential new drugs prior to
pre-clinical testing in more traditional mouse models of cancer.  This new
approach could provide important insights into the development of new cancer
therapies as well as potentially reduce the number of pre-clinical animals
involved in the drug development process.

Principal investigator Dr Kyra Campbell of the University is the beneficiary
of a three-year grant from the National Centre for the Replacement, Refinement
and Reduction of Animals in Research (NC3Rs), awarded in December 2021, which
has funded a significant programme of research at the University and other
institutions where her co-investigators are based.

The University successfully applied for funding under the UK Research and
Innovation (UKRI) Higher Education Innovation Funding (HEIF) scheme, part of
which will be used to retain Physiomics for a pilot project to analyse data
generated by its innovative new testing platform in order to better understand
how the platform might guide later stages of pharmaceutical research into
cancer therapies, including pre-clinical and human studies.

The project is expected to be concluded over the next two months, and a
longer-term collaboration is currently under discussion.

 

Physiomics CEO, Dr Jim Millen commented:

"We are delighted to have been selected by The University of Sheffield to
support this highly innovative research program with our analytical and
modelling capabilities.  We look forward to working with Dr Campbell and her
colleagues and believe that both our analytical capabilities, as well as our
contacts and experience within the pharmaceutical industry, could add real
value to the initiative."

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAURSVROUUVOAR